2Bonner JA, Sloan JA, Rowland KM, et al. Significace of neuron-specific enolase levels before and during therapy for small cell lung career. Clin Cancer Res, 2000,6 : 597-601.
3Pujol JL,Boher JM,Grenier J,et al. Cyfra 21-1,neuron specific enolase and prognosis of non-small cell lung carcer: prospective study in 621 patients. Lung Cancer, 2001,31 : 221-231.
4Karnak D, Ulubay G, Kayacan O, et al. Evaluation of Cyfra 21-1: A Potential tumor marker for non-small cell lung carcinomas. Lung, 2001,179:57-65.
5Ebert W, Muley T. CYFRA21-1 in the follow-up of in operable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res, 1999,19:2669-2672.
6Ando S, Kimura H, Iwai N,et al. Optimal combination of seven tumor makers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res, 2001,21 : 3085-3092.
7Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of Progastrin-releasing peptide (proGRP)and neuron specific enolase (NSE)in diagnosis and prognosis of small-cell lung cancer 9 (SCLC). Lung cancer, 2001,32:61-69.
8Stieber P, Dienemann H, Schalhorn A, et al. Pro-gastrin-releasing peptide (proGRP)a useful marker in small cell lung carcinomas. Anticancer Res, 1999,19: 2673-2678.
9Goto K, Kodama F, Hojo F, et al. Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer, 1998, 82:1056-1061.
10Ferrer J,Villarino MA,Encabo G,et al. Diagnostic utility of CYFRA21-1,carcinoembryonic antigen,CA125,neuron specific enolase,And squmous cell antigen leval determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999,86 : 1488-95.
1Castano-Vidrialcs JL,Amores-Antequera C.Use of pleura fluid Creactive protein in laboratory diagnosis of pleural effusions.Eur J Med,1992,1(4):201-207.
